Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving melphalan and bortezomib before and after a stem cell transplant stops the
growth of abnormal cells by stopping them from dividing or killing them. Giving
colony-stimulating factors and certain chemotherapy drugs, helps stem cells move from the
bone marrow to the blood so they can be collected and stored. Chemotherapy and monoclonal
antibody therapy is then given to prepare the bone marrow for the stem cell transplant. The
stem cells are then returned to the patient to replace the blood-forming cells that were
destroyed by the chemotherapy.
PURPOSE: This phase II trial is studying how well giving melphalan together with bortezomib
followed by stem cell transplant works in treating patients with primary systemic
amyloidosis.